These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24593744)

  • 1. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Med Phys; 2014 Mar; 41(3):033502. PubMed ID: 24593744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy.
    Mattonen SA; Tetar S; Palma DA; Louie AV; Senan S; Ward AD
    J Med Imaging (Bellingham); 2015 Oct; 2(4):041010. PubMed ID: 26835492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
    Mattonen SA; Palma DA; Johnson C; Louie AV; Landis M; Rodrigues G; Chan I; Etemad-Rezai R; Yeung TP; Senan S; Ward AD
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1121-8. PubMed ID: 26907916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting adenocarcinoma recurrence using computational texture models of nodule components in lung CT.
    Depeursinge A; Yanagawa M; Leung AN; Rubin DL
    Med Phys; 2015 Apr; 42(4):2054-63. PubMed ID: 25832095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
    Starkov P; Aguilera TA; Golden DI; Shultz DB; Trakul N; Maxim PG; Le QT; Loo BW; Diehn M; Depeursinge A; Rubin DL
    Br J Radiol; 2019 Feb; 92(1094):20180228. PubMed ID: 30457885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer.
    Huang K; Senthi S; Palma DA; Spoelstra FO; Warner A; Slotman BJ; Senan S
    Radiother Oncol; 2013 Oct; 109(1):51-7. PubMed ID: 23953413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature.
    Huang K; Dahele M; Senan S; Guckenberger M; Rodrigues GB; Ward A; Boldt RG; Palma DA
    Radiother Oncol; 2012 Mar; 102(3):335-42. PubMed ID: 22305958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?
    Mattonen SA; Ward AD; Palma DA
    Br J Radiol; 2016 Sep; 89(1065):20160113. PubMed ID: 27245137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics.
    Dammak S; Gulstene S; Palma DA; Mattonen SA; Senan S; Ward AD
    Sci Rep; 2024 Feb; 14(1):3758. PubMed ID: 38355768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
    Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
    Peulen H; Mantel F; Guckenberger M; Belderbos J; Werner-Wasik M; Hope A; Giuliani M; Grills I; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):134-41. PubMed ID: 27325481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy.
    Sawyer B; Pun E; Samuel M; Tay H; Kron T; Bressel M; Ball D; Siva S
    J Med Imaging Radiat Oncol; 2015 Apr; 59(2):207-15. PubMed ID: 25601133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
    Ronden MI; van Sörnsen de Koste JR; Johnson C; Slotman BJ; Spoelstra FOB; Haasbeek CJA; Blom G; Bongers EM; Warner A; Ward A; Palma D; Senan S
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):115-121. PubMed ID: 29102278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.